Title: Topoisomerase I Inhibition Serves as a Tumor Vaccine by Inducing the ERVs-dsRNA-Interferon Pathway
Pharmacological Research · 2026-11 · 109750
DOI: 10.1016/j.phrs.2026.109750 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Research, 2026-11. Verfasst von Yanting Lin und 14 weiteren Autor:innen. Beteiligte Einrichtung: China Pharmaceutical University. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jiangsu Province Natural Science Foundation, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Double-stranded RNA (dsRNA) can activate potent anti-tumor immunity, but its clinical translation remains challenging. We sought to identify clinically applicable strategies to induce endogenous dsRNA and enhance anti-tumor immune responses. Here, we integrated genome-wide CRISPR-Cas9 screening data with the Therapeutic Target Database (TTD) and identified Topoisomerase I (TOP1) as a potential inducer of dsRNA. Mechanistically, we found that TOP1 was associated with suppression of endogenous retroviruses (ERVs) in an enzyme activity-dependent manner, and this was accompanied by "viral mimicry" through the induction of dsRNA. Pharmacological inhibition of TOP1 using Irinotecan (CPT-11) triggered dsRNA accumulation across cancer models, including patient-derived organoids (PDOs), activating the RIG-I/MDA5-MAVS pathway and antiviral interferon responses (Type I/III IFNs, ISGs). scRNA-seq revealed that CPT-11 remodeled the tumor microenvironment, promoting infiltration of dendritic cells (DCs), macrophages, and T cells. Combining CPT-11 with PD-1 blockade in "cold" tumors dramatically improved survival. CPT-11 also generated a potent in situ vaccine effect, establishing immunological memory that prevented tumor rechallenge. Moreover, tumor cells pretreated with CPT-11 in vitro were also able to exert a vaccine-like effect, inhibiting the growth of subsequently inoculated tumors. Collectively, our findings support the repurposing of TOP1 inhibitors such as CPT-11 to harness dsRNA-mediated immune activation for more effective cancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- China Pharmaceutical University.
- Shandong University.
- Accurate International Biotechnology Limited Company Author Institution is Unverified.
- Nanjing, CHINA. Electronic address: gaoxinghua@cpu.edu.cn.
Förderung
- Jiangsu Province Natural Science Foundation
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Lin, Y., Ren, Y., Jing, D., Gao, R., Tian, S., Liu, Y., Jiang, X., Zhao, Q., Gao, Z., Zhu, Y., Cai, J., Xiao, P., Yang, Y., Cao, Q., & Gao, X. (2026). Title: Topoisomerase I Inhibition Serves as a Tumor Vaccine by Inducing the ERVs-dsRNA-Interferon Pathway. Pharmacological Research, 109750. https://doi.org/10.1016/j.phrs.2026.109750
Vancouver
Lin Y, Ren Y, Jing D, Gao R, Tian S, Liu Y, et al. Title: Topoisomerase I Inhibition Serves as a Tumor Vaccine by Inducing the ERVs-dsRNA-Interferon Pathway. Pharmacological Research. 2026:109750. doi:10.1016/j.phrs.2026.109750
BibTeX
@article{Lin2026,
author = {Lin, Yanting and Ren, Yiming and Jing, Dongquan and Gao, Rui and Tian, Siyu and Liu, Yingming and Jiang, Xingyu and Zhao, Qixiang and Gao, Zhenhua and Zhu, Yu and Cai, Jian and Xiao, Pingting and Yang, Yong and Cao, Qiuhua and Gao, Xinghua},
title = {Title: Topoisomerase I Inhibition Serves as a Tumor Vaccine by Inducing the ERVs-dsRNA-Interferon Pathway},
journal = {Pharmacological Research},
year = {2026},
pages = {109750},
doi = {10.1016/j.phrs.2026.109750}
}
EUVIMED